GSK plc has completed its previously announced acquisition of IDRx Inc., a Boston-based, clinical-stage biopharmaceutical ...

GSK (GSK) plc announced that it has completed the acquisition of IDRx, Inc., a Boston-based, clinical-stage biopharmaceutical company dedicated ...

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, ...

GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.

GSK on Monday also said it has start the GBP2 billion buyback programme that it announced earlier this month, starting with an initial GBP700 million tranche.

It forecasts that the repurchases - which are due to complete in 18 months - will boost core earnings by 6% to 8% in 2025 ...

(Alliance News) - Stock prices in London opened mostly flat on Monday, while across the channel Germany's election results have sparked uncertainty but also hopes of economic stimulus. The FTSE 100 ...

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare gastrointestinal stromal tumour (GIST). The rumoured ...

Friday’s weak performance by US equities means London’s FTSE 100 index is set for a subdued start to the new week. The FTSE ...

The FTSE 250 business's stock jumped 4.7%, or 6.3p, to 141.8p as investors bet it could be next food delivery group to be ...

GSK’s share price has fallen a long way on a combination of factors, but do its recent strong results leave its current price ...